Anti IL-17A/F NanoAb - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen
Alternative Names: anti-IL-17 VHH antibody; Anti-IL-17A/F NanoAbsLatest Information Update: 22 Aug 2024
At a glance
- Originator The Max Planck Society; University Medical Center Gottingen
- Developer Scinai Immunotherapeutics
- Class Anti-inflammatories; Antibodies; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis
Most Recent Events
- 15 Aug 2024 Anti IL-17A/F NanoAb - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen is available for licensing as of 15 Aug 2024. www.scinai.com
- 23 Jul 2024 Scinai Immunotherapeutics received positive regulatory feedback from the Paul Erlich Institute (the PEI) of Germany for IMPD filing with the European Medicines Agency (EMA) for Plaque psoriasis
- 23 Jul 2024 BiondVax Pharmaceuticals plans a phase I/IIa trial in Plaque Psoriasis in the second half of 2025 (Intradermal, Injection)